Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X
July 27, 2021 02:00 ET
|
Artios Pharma, Inc.
Funding propels Artios’ ability to progress beyond synthetic lethality and to continue the exploitation of the full spectrum of oncology vulnerabilities presented by the DNA Damage Response through...
Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications
June 17, 2021 11:00 ET
|
Artios Pharma, Inc.
Artios’ small molecule Polθ inhibitor elicits BRCA-gene synthetic lethality and PARP inhibitor synergyGenetic screening reveals biomarkers within the PARP inhibitor resistance setting to enable...
Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies
April 07, 2021 02:00 ET
|
Artios Pharma, Inc.
Novartis to leverage Artios’ discovery platform to identify DDR targets for use with Novartis’ proprietary radioligand therapies.Artios to receive US$20 million up-front payment in addition to near...